Description: Maravai LifeSciences Holdings, Inc. operates as a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products used in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry. The company serves biopharmaceutical companies, and other emerging biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Home Page: www.maravai.com
MRVI Technical Analysis
10770 Wateridge Circle
San Diego,
CA
92121
United States
Phone:
858 546 0004
Officers
| Name | Title |
|---|---|
| Mr. Carl W. Hull | Co-Founder and Exec. Chairman & Interim CEO |
| Mr. Kevin M. Herde | Exec. VP & CFO |
| Mr. Kurt Oreshack | Exec. VP, Gen. Counsel & Sec. |
| Ms. Christine Dolan | Chief Operating Officer of Biologics Safety Testing |
| Mr. Brian Neel | Chief Operating Officer of Nucleic Acid Production |
| Dr. Peter Michael Leddy Ph.D. | Exec. VP & Chief Admin. Officer |
| Ms. Debra Hart | Sr. Director of Investor Relations |
| Ms. Doreen Pippen | VP of Marketing |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 30.3951 |
|---|---|
| Trailing PE: | 7.8448 |
| Price-to-Book MRQ: | 3.9507 |
| Price-to-Sales TTM: | 4.2247 |
| IPO Date: | 2020-11-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 470 |